Serge A Jabbour (Serge Jabbour)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 14

Top Topics

Randomized Controlled Trial

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Jean-Etienne Poirrier, Juliana L Meyers, Saurabh P Nagar, Brandon J Patterson, Lisa I Glasser, Serge A Jabbour
Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Diabetes care 45 (11) (2022)
Kamlesh Khunti F MedSci, Serge A Jabbour, Xavier Cos, Sunder Mudaliar, Christian Mende, Marc Bonaca, Paola Fioretto
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes, obesity & metabolism 24 (7) (2022)
Serge A Jabbour, Juan Pablo Frias, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C David Sjöström, Cristian Guja
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes care 43 (10) (2020)
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Ricardo Garcia-Sanchez, Nalina Dronamraju, Serge A Jabbour, Marcus Lind
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial. Diabetes, obesity & metabolism 22 (6) (2020)
Eleuterio Ferrannini, Simona Baldi, Juan Pablo Frias, Cristian Guja, Elise Hardy, Enrico Repetto, Serge A Jabbour, Muhammad Abdul-Ghani
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study. Diabetes, obesity & metabolism 22 (1) (2019)
Francesco Rubino, Enrico Repetto, Cristian Guja, Elise Hardy, Jenny Han, Serge A Jabbour, Eleuterio Ferrannini
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (3) (2019)
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge A Jabbour, Marcus Lind
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes care 42 (8) (2019)
Serge A Jabbour, Juan P Frías, Elise Hardy, Azazuddin Ahmed, Hui Wang, Peter Öhman, Cristian Guja
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes care 41 (10) (2018)
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge A Jabbour, Niki Arya, Lars Hansen, Fredrik Thorén, Anna Maria Langkilde, null null
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes care 41 (9) (2018)
Juan Pablo Frias, Elise Hardy, Azazuddin Ahmed, Peter Öhman, Serge A Jabbour, Hui Wang, Cristian Guja
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes, obesity & metabolism 20 (6) (2018)
Cristian Guja, Juan Pablo Frias, Aniko Somogyi, Serge A Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes, obesity & metabolism 20 (7) (2018)
Serge A Jabbour, Juan Pablo Frias, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Peter Öhman
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes, obesity & metabolism 20 (6) (2018)
Serge A Jabbour, Jochen Seufert, André J Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes, obesity & metabolism 20 (3) (2017)
Herve Caspard, Serge A Jabbour, Niklas Hammar, Peter Fenici, John J Sheehan, Mikhail Kosiborod
Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. Diabetes, obesity & metabolism 20 (3) (2017)